Kori Talbott, PharmD PGY1 Pharmacy Resident Eastern States May 2013 Incorporation of REMS (Risk Evaluation and Mitigation Strategies) into daily clinical.

Slides:



Advertisements
Similar presentations
Module N° 4 – ICAO SSP framework
Advertisements

Tips to a Successful Monitoring Visit
Work Hours Restrictions as an Ethical Dilemma for Residents Robert O. Carpenter, M.D. Mary T. Austin, M.D. John L. Tarpley, M.D. Kimberly D. Lomis, M.D.
Medication Management
HIPAA Privacy Training. 2 HIPAA Background Health Insurance Portability and Accountability Act of 1996 Copyright 2010 MHM Resources LLC.
REMS Update NORD Corporate Council Meeting May 14, 2013
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
Exempt Research Mary Banks BS, BSN IRB Director CRC IRB and BUMC IRB.
Patient Attitudes Regarding Willingness to Participate in Clinical Research: Results from the Patient Attitude Survey Study (PASS) Lala R. Hussain, Tiffany.
Sixth Annual Meeting March 12, :00am to 4:00pm Crowne Plaza National Airport Arlington, VA INTERMACS Annual Meeting March 2012.
Title slide Georgia Hospital Engagement Network Healthcare Acquired Condition Affinity Group June 19, 2013 Presenter: Dr. Teresa Pounds, PharmD, BCNSP.
Medication Reconciliation Networking Session Steve Rough, MS., RPh. Director of Pharmacy University of Wisconsin Hospital and Clinics.
America’s Health Insurance Plans Health Insurance Plans Approaches to Asthma Management: 2006 Assessment Supported through a cooperative agreement with.
INSTITUTIONAL PHARMACY PRACTICE STANDARDS
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
Medication History: Keeping our patients safe. How do we get all of the correct details?
Clinical Pharmacy’s Role in Research Trials Sheree Miller Pharm.D. Investigational Drug Service University of Washington Medical Center.
1 Alvimopan RiskMAP Joyce Weaver, Pharm.D., BCPS Office of Surveillance and Epidemiology.
Standard 5: Patient Identification and Procedure Matching Nicola Dunbar, Accrediting Agencies Surveyor Workshop, 10 July 2012.
Is this Research? Exempt? Expedited?
Pharmacy and Therapeutics Committee
Current and Emerging Use of Clinical Information Systems
2015 National Patient Safety Goals and the Older Adult Julie Pope Nurs 4292 Spring I Columbus State University.
by Joint Commission International (JCI)
FDA REMS Program REMS: Risk Evaluation & Management Strategy
Impact Health NDAC Meeting Stewart Levy R.Ph. January 14, 2005.
Integrating HIPAA Into Your Compliance Program Fifth Annual National Congress on Health Care Compliance February 7, 2002 Glenna S. Jackson Vice President.
Electronic Health Records and Clinical Decision Support Systems Impact on National Ambulatory Care Quality Max J. Romano, BA; Randall S. Stafford, MD,
Increasing Pharmacists reporting of adverse medication incidents Being Ready for new risks and Opportunities Prepared by Tim Garrett Northern Sydney Central.
Common Audit Findings UTHSC Institutional Review Board (IRB)
Proband Incorporating Structured Pedigree Data into Genomic Medicine Through a Pedigree and Family History iPad App Jeffrey M. Miller 1, Michael J. Italia.
FOCUSFOCUS. CPOE at Cedars-Sinai What Worked, What Didn’t Cedars-Sinai Medical Center Los Angeles, California C S Paul Hackmeyer, M.D. Chief of Staff.
2012 Role Delineation Study: What is it, and why do it?
Module N° 8 – SSP implementation plan. SSP – A structured approach Module 2 Basic safety management concepts Module 2 Basic safety management concepts.
Safety Groups Program 2009 Start of Year. Agenda Safety Group Objectives Safety Group Program Requirements 3 rd edition Employer Guidelines / Element.
For Pain or Not for Pain: Methadone Madness
Evidence, guidelines and practice: the way forward in a digital age SYDNEY 11 April, 2013 Bill Runciman Professor – Patient Safety & Healthcare Human Factors.
Standard 4: Medication Safety Advice Centre Network Meeting Margaret Duguid Pharmaceutical Advisor February 2013.
FDA Risk Management Workshop: Concept Paper: Risk Management Programs April 10, 2003 Gary C. Stein, Ph.D. Director of Federal Regulatory Affairs American.
Office of Public Health Preparedness and Response Division of Strategic National Stockpile Ben Erickson Public Health Analyst Inventory Management Tracking,
Integrate Risk Evaluation & Mitigation Strategies (REMS) with Health Management Craig Kephart, President & CEO Centric Health Resources, Inc. July 15,
Monitoring and Evaluating SES Provider Programs
International Civil Aviation Organization RSOOs and the new ICAO Strategies and Programmes Simon Clegg General Manager Government & Strategy Civil Aviation.
Origin and Process of Utah Guidelines Anna Fondario, MPH Utah Department of Health Violence and Injury Prevention Program.
This class cannot be shared or copied without the written permission of PracticeWorks Systems, LLC.
Guidance Training CFR §483.75(i) F501 Medical Director.
MDIC 1 George Serafin Deloitte & Touche LLP MDIC Open Forum Quality System Maturity Model Update.
CTMB Guidelines (Rev. October 2006) Section 5: Conducting the Quality Assurance Audit.
July 15, Postmarketing Safety Evaluation of Approved Drugs and Risk Management Victor F. C. Raczkowski, MD, MS Director, Office of Drug Safety July.
October 9 th, 2015 University of Pennsylvania TIES Cancer Research Network Y3 Face to Face Meeting U24 CA Session 5 Regulatory Update.
RESTICTED DRUGS Risk Evaluation and Mitigation Strategies--REMS
October 28, F OOD AND DRUG ADMINISTRATION AMENDMENTS ACT OF 2007 (FDAAA) and Risk Evaluation and Mitigation Strategies (REMS) Presented to the Ninth.
Pharmacy & The IRB Linda Sailor, BS, PharmD Rania Sadaka, BS, PharmD May 2015.
Improving the Quality of Prenatal Care at the WMed FM Residency Clinic Susan Jevert, DO Homer Stryker MD School of Medicine Department of Family and Community.
Reviewing Wisconsin’s “Gaps” Justin Guthman PharmD Pharmacy Operations Coordinator Froedtert Hospital Milwaukee Wisconsin.
Wait Time Project Implementation Strategy. Implementation Plan: Goals 1.To educate and provide clarification around the wait time project, wait time definitions,
NANCY CHOBIN, RN, AAS, ACSP, CSPM, CFER CHOBIN & ASSOCIATES CONSULTING HOT TOPICS IN STERILIZATION AND DISINFECTION.
Private and confidential Community Pharmacy Future Four-or-more medicines support service Update on progress and next steps Approved18 th June 2012 This.
COMPARISON OF ADVERSE EFFECT PROFILES OF PAIN REGIMENS WITH AND WITHOUT INTRAVENOUS ACETAMINOPHEN IN TOTAL HIP AND KNEE ARTHROPLASTY PATIENTS Alyssa J.
Comparison of pharmacy technician versus nurse obtained medication histories in the emergency department Marija Markovic, Pharm.D. PGY-1 Pharmacy Practice.
Pharmacist Impact on Patient Mortality and Advanced Cardiac Life Support Guideline Compliance During In-Hospital Cardiac Arrest Joseph Cavanaugh, PharmD.
Baseline Assessment of Nurses’ Experiences and Attitudes regarding Expanded HIV Testing in the Emergency Department at LIJ November 2014 Jenny Doyle,NSLIJ.
Special Needs Plans (SNP) Overview of SNP Assessment and S&P Measures June 2010.
REDCap Basics Michael Gleason, Ph.D. Emily Glenn, MSLS
*Risk Evaluation and Mitigation Strategy
Assessment of Knowledge of Recommended Health Management Behaviors
Does the Beer’s Criteria Influence Prescribing for Geriatric Patients?
CLICK TO GO BACK TO KIOSK MENU
Risk Management: why and how to protect your health center
Registered Nurse’s Use of HIT, 2006: Findings from a National Survey
Presentation transcript:

Kori Talbott, PharmD PGY1 Pharmacy Resident Eastern States May 2013 Incorporation of REMS (Risk Evaluation and Mitigation Strategies) into daily clinical practice in the inpatient hospital setting: results of an online survey

Study Objectives  Determine how many institutions are compliant with REMS guidelines  Based on four areas of compliance, assess if the presence of policies and procedures regarding REMS would help hospitals to achieve compliance with REMS requirements  Determine current practice regarding REMS in an inpatient hospital setting

Background  Food and Drug Administration Amendments Act of 2007 –Response to Vioxx recall in 2004 –Intent is to “ensure that the benefits of a drug or biological product outweigh its risks” –Civil, criminal, and administrative liabilities  Potential REMS program components: –Communication Plan –Medication Guide –Implementation System –Elements to Assure Safe Use (EASU) “Approved Risk Evaluation and Mitigation Strategies (REMS)” Postmarket Drug Safety Information for Patients and Providers. Food and Drug Administration, 25 February Web. 18 March Traynor, Kate. "Experts Say REMS Assessments Need Work." ASHP Pharmacy News [White Oak, MD] 15 July 2012, n. pag. Web. 23 Aug

Background  Potential Elements to Assure Safe Use (EASU) Program Components “Approved Risk Evaluation and Mitigation Strategies (REMS)” Postmarket Drug Safety Information for Patients and Providers. Food and Drug Administration, 25 February Web. 18 March

Background  Pharmacy News in ASHP: Experts say REMS Assessments Need Work – July 2012 –Lack of official FDA policies on REMS programs, goals, and implementation  Common REMS drugs and programs –Tikosyn: Tikosyn In Pharmacy Systems (TIPS) Program –Alglucosidase alfa: Lumizyme ACE Program –Fentanyl: Transmucosal Immediate-Release Fentanyl (TIRF) Program Traynor, Kate. "Experts Say REMS Assessments Need Work." ASHP Pharmacy News [White Oak, MD] 15 July 2012, n. pag. Web. 23 Aug

Methods  Study Design –IRB Approved –Expert Reviewed –Anonymous, 25 question web-based survey –Distribution through LISTSERVS and targeted s to local hospital pharmacies –Survey data collected via REDCap  Time period –November 2012 – January 2013 Paul A. Harris, Robert Taylor, Robert Thielke, Jonathon Payne, Nathaniel Gonzalez, Jose G. Conde, Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform Apr;42(2):

Methods  Inclusion Criteria –Completed surveys  Exclusion Criteria –Incomplete surveys –Institutions did not indicate dispensing of any listed REMS drugs  Statistical Tests –Pearson Chi Square –Fisher Exact Test –P-values less than 0.05 considered significant

Methods  Survey questions – Presence of policy and procedures –REMS drugs dispensed –Extent of compliance with various REMS standards –Responsibilities for implementation –Implementation tools –Procedures for auditing for compliance

Results  50 surveys returned  Data analysis based on 48 surveys  Policy and Procedures (P&P) pertaining to REMS Number (n = 48)Percent Institutions with P&P % Institutions with out P&P %

REMS Medications Dispensed

Results REMS requirements based on dispensed medications Compliance n = 48 Provision of mandatory Medication Guide 39.6% M andatory prescriber enrollment/training 79.2% Mandatory patient enrollment/acknowledgement 77.1% Mandatory pharmacy/hospital enrollment 93.8% Compliance with all four areas35.4%

Overall Compliance With P&P n = 34 (%) Without P&P n = 14 (%) Overall n = 48 (%) How many institutions are compliant with all four elements? Compliant with zero elements01 (7.1%)1 (2.1%) Compliant with one element3 (8.8%)2 (14.3%)5 (10.4%) Compliant with two elements5 (14.7%)4 (28.6%)9 (18.8%) Compliant with three elements12 (35.3%)4 (28.6%)16 (33.3%) Compliant with all four elements 14 (41.2%) 3 (21.4%) 17 (35.4%) Pearson Chi SquareP = not calculated (“n” too low) Fisher Exact TestTwo tailed P = 0.27

Results – Areas of Survey Consensus >50% Respondent Agreement Policies and Procedures Pharmacy primarily responsible for development. REMS alerts Multiple alerts: order entry/verification and administration process. Medication Guides The nurse and/or prescriber reviews prior to the first dose. Prescriber Enrollment Only certain prescribers are enrolled and pharmacy verifies enrollment. Patient Enrollment Prescribers ensure enrollment and pharmacy verifies enrollment. Restricted Drug Distribution Programs Pharmacy management is responsible for enrolling pharmacy

Results – Areas of Survey Disparities <50% Respondent Agreement Updates and Releases Who is responsible for maintaining updates and releases? How often should updates be reviewed? Medication Guides How are paper copies generated?

Discussion  Barriers: –Lack of knowledge –Complex programs –Moving target  Potential Solutions: –Create a policies and procedures –Designate individuals or task force –Advocate for enforcement

Study Limitations  Survey study design can innately have limitations –Anonymity –Respondent  Small number of responders likely did not allow for significant findings

Conclusions  Two-thirds of institutions are non-compliant with REMS requirements  Statistically, the presence of a policies and procedures did not significantly impact overall compliance

Acknowledgements  Elora Hilmas, PharmD, BCPS  Joseph Peoples, PharmD  Robert Akins Jr., PhD, FAHA

Kori Talbott, PharmD PGY1 Pharmacy Resident Eastern States May 2012 Questions? Please